Join the 'Sargramostim' group to help and get support from people like you.
Posted 4 Nov 2014 by Drugs.com
TUESDAY, Nov. 4, 2014 – Patients with advanced melanoma may live longer when treated with a combination of the cancer drug Yervoy and the immune system booster sargramostim, a new study finds. Patients given the two drugs had a median survival of 17.5 months, compared to 12.7 months for those on Yervoy (ipilimumab) alone. At one year, overall survival was nearly 69 percent for those on the ...
Ask a Question
Related Condition Support Groups
Neutropenia Associated with Chemotherapy, Aplastic Anemia, Bone Marrow Transplantation, Bone Marrow Transplantation, Failure or Engraftment Delay, Bone Marrow Transplantation, Myeloid Reconstruction, Neutropenia Associated with Radiation